Key Takeaways
- Solid quarter, capacity-constrained: Standalone revenue grew 7.5% YoY despite losing ~₹45 crores from one unit being down; the unit has since restarted and the other is expected soon.
- Fluorination is the growth engine: Management expects $220–260 mn in revenue from the fluorination pipeline over 3–5 years, unlocked by the Tanfac acquisition, with revenue building over the next 1–2 years.
- Europe+1 is real and accelerating: Two contracts signed with European companies in Q3, representing ~₹100 crores over 4–5 years, as customers move products out of Europe permanently.
- Cash flow turning the corner: Operating cash flow hit ₹57 crores in Q3, higher than PAT, as working capital days dropped; management expects the trajectory to continue toward ~200 days.
- What to watch next quarter: The pace of fluorination product launches (5 planned for Q4), conversion of LOIs into contracts, and whether the second downed unit restarts on schedule.
Fluorination: The Next Growth Cycle
- Pipeline unlocked by Tanfac: Customers had asked Anupam to start fluorination only once the Tanfac acquisition was in place; after the deal closed, customers returned and the business began.
- Revenue ambition: Management guided to $220–240 mn in fluorination revenue over the next 3–5 years, with limited contribution early on and a significant ramp as products move through their growth curves.
- Capacity build-out: One fluorination plant targeted to start by March '24, though management requests not being held to that date until at least one more quarter for better visibility. Total capex of ~₹420 crores planned for fluorination.
- Long-term scale: Five years down the line, fluorination will be a sizable business, per management's stated ambition.
Anand Desai: "We understand that there is a time lag to introducing these products, but we have been working on these products since last three, four years. It is only that the customers had asked us to start the business only once the Tanfac acquisition was in place, which is there now, and this is how the business has started."
Europe+1: Structural Demand Shift
- Two contracts signed in Q3: Leading European companies moved products directly out of Europe to Anupam's portfolio, representing ~₹100 crores of revenue over the next four to five years.
- Speed of execution: Anupam's agility in responding to customer urgency enabled the wins; products were moved in a very short time period.
- Permanent shift, not temporary: Once a product moves out of Europe to India or China, it does not go back; these are strategic, long-term moves, not short-term fixes.
- Energy economics support the trend: Management believes the new normal for energy prices in Europe will be structurally higher than the old normal, reinforcing the case for relocation.
Vishal Thakkar: "this is a product, which is coming straight out of Europe to our portfolio, and we could do it in a very short time period. And that's where we were and Europe+1 movement of strategy or whatever, we want to call it as, that has now started playing out."
Product Pipeline & Commercialization
- 50 products commercialized: One more product under LOI was commercialized during Q3, bringing the total tally to 50.
- Near-term launch cadence: 14 products in the pipeline to be commercially launched in the next 12–18 months; 3–5 planned for Q4 FY23, the majority in fluorination chemistry.
- Steady-state cadence: 6–8 molecules expected to be commercialized every year from a product pipeline of ~90 products.
- LOI conversion visibility: Management expects more conclusion of LOIs for new products and conversion of LOIs into contracts in coming quarters, increasing revenue visibility. LOI/contract revenue expected to ramp to at least ₹200 crores in FY24, reaching full value of ~₹475 crores in FY25.
Financial Health & Margins
- Cash flow inflection: Generated ₹57 crores in operating cash flow in Q3, higher than PAT, as working capital requirements came down. Nine-month operating cash flow stood at ₹155 crores.
- Working capital trajectory: Inventory days are dropping and will continue to drop; full-year guided around 230–240 days, with a path to ~200 days and below over the next three to five quarters.
- Margin sustainability: EBITDA margin at 28% consolidated, lower due to Tanfac's lower margin profile. Management focuses on PBT/EBITDA levels rather than gross margin alone, citing the transparent cost-plus business model with complex chemistry as margin support.
- Interest cost declining: Sequential reduction of a couple of crores driven by working capital efficiency; expected to improve further.
- Fully funded growth: FY24 capex of ~₹300 crores and an additional ~₹250 crores over the following 18–24 months will be fully funded; no additional debt needed, and the business will generate more cash.
Vishal Thakkar: "We are fully funded. In fact, I will be generating more cash out of my business because if you look at it, I'm fairly funded on the day one. We will need no debt to grow, do the capex that we have budgeted for now."
Revenue Growth & Demand Visibility
- Standalone growth guidance: 25%+ revenue growth on Anupam standalone basis; Tanfac shall be over and above that.
- FY23 exit rate: Annual top-line growth expected at least 300–400 bps above the nine-month figure of 21%, implying ~24–25% for the full year.
- No demand slowdown: Management sees no revising of demand outlook from customers; the net effect from the Europe situation has been beneficial. Volumes for FY24 are practically there, with no major issues expected for the next three to four quarters.
- Customer concentration moderating: Top 10 customers contributed 91% of total revenue; management plans to moderate this as more products and customers are added.
- Billing shift progressing: 60% of contracted revenue moved to six-month billing; the rest is under negotiation, contributing to working capital improvement.
Vishal Thakkar: "we have a visibility, the contracts have a business and the volume is practically there and it's about the price that we revise every six and 12 months as the case maybe."
Tanfac Integration & Outlook
- Consolidation impact: Q3 FY23 consolidated revenue jumped 44% YoY primarily because Q3 FY22 did not include Tanfac Industries. Consolidated EBITDA margin was lower at 28% due to Tanfac's lower margin profile.
- Anupam's value-add: Anupam is providing technical expertise, marketing expertise, and product knowledge to Tanfac.
- Independent growth path: Tanfac will have its own growth journey and will deploy its own capital for new capex; management expects it to do a good set of numbers over the next few years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone revenue growth | 25%+ on Anupam standalone basis (Tanfac over and above) | FY24 |
| Fluorination pipeline revenue | $220–260 mn total | Next 3–5 years |
| LOI/contract revenue ramp | At least ₹200 crores in FY24, ~₹475 crores in FY25 | FY24 / FY25 |
| Product launches | 3–5 products in Q4 FY23; 6–8 molecules every year thereafter | Q4 FY23 / annual |
| FY24 capex | ~₹300 crores | FY24 |
| Subsequent capex | ~₹250 crores | Next 18–24 months |
| Working capital days | ~200 days and below | Next 3–5 quarters |
| FY23 annual revenue growth | At least 300–400 bps above 9M figure of 21% (~24–25%) | FY23 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Consolidated operating revenue | ₹382.7 cr, up 44% YoY (Q3 FY22 base did not include Tanfac) |
| Standalone operating revenue | ₹286.2 cr, up 7.5% YoY |
| Consolidated EBITDA | ₹108 cr, up 35% YoY |
| Consolidated EBITDA margin | 28%, lower due to Tanfac's lower margin profile |
| Standalone EBITDA margin | 29% |
| Consolidated PAT | ₹54.4 cr, up 44% YoY |
| Standalone PAT | ₹38.6 cr, up 2% YoY |
| Operating cash flow (quarter) | ₹57 cr, higher than PAT for the quarter |
| Operating cash flow (9 months) | ₹155 cr |
| Life Sciences segment share | 82% of total revenue, ~₹231 cr |
| Exports share | 62% of total revenue |
| Top 10 customer concentration | 91% of total revenue, across 24 products |
| Revenue loss from plant unavailability | ~₹45 cr in Q3; potential further loss of ₹5–10 cr in Q4 |
| Products commercialized under LOIs/contracts (cumulative) | 4 core products; total product tally reached 50 |
| Products planned for Q4 commercialization | 5 products, majority in fluorination chemistry |
| Revenue from FY22 LOIs/contracts (9 months) | ₹75–80 cr; expected to ramp to ₹200+ cr in FY24 and full ₹475 cr in FY25 |
| Fluorination revenue opportunity | $220–260 mn annual revenue over next 3–5 years |
| FY24 capex guidance | ₹300 cr; additional ₹250 cr in the following year |
| FY23 capex guidance | ₹170–175 cr; ₹100 cr deployed in 9 months |
| Contracted revenue on 6-month billing | ~60% |